Linked Life Data

2154857

Source:http://linkedlifedata.com/resource/pubmed/id/2154857

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1 Suppl 2
pubmed:dateCreated
1990-3-26
pubmed:abstractText
Twenty-six previously treated patients with refractory small cell lung cancer (SCLC) were entered into a Hoosier Oncology Group phase II trial of daily oral etoposide 50 mg/m2/d. Twenty-five patients had prior exposure to cisplatin plus etoposide, and 14 of the 26 patients (54%) had prior therapy with CAV (cyclophosphamide, doxorubicin, and vincristine). Nonhematologic toxicity was mild; the dose-limiting toxicity was granulocytopenia. One complete response and five partial responses were seen (duration, 6 to 20 weeks), for an overall response rate of 23%. We conclude that daily oral etoposide is a well-tolerated and easily administered drug in refractory SCLC and has definite therapeutic activity.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0093-7754
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
32-5
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1990
pubmed:articleTitle
Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study.
pubmed:affiliation
Hoosier Oncology Group, Walther Cancer Institute, Indianapolis, IN 46208.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.